ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
3
views
0
references
Top references
cited by
3
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,805
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: the PRONOUNCE trial study design
Author(s):
C Melloni
,
Melloni
,
SF Slovin
,
A Blemings
,
SG Goodman
,
CP Evans
,
J. Nilsson
Publication date:
2020
Journal:
JACC: CardioOncol
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Procedural speed in criminal law
Data availability:
Comments
Comment on this article
Sign in to comment
Similar content
1,805
Re: cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
Authors:
David Penson
783 DEGARELIX INDUCTION FOLLOWED BY LEUPROLIDE MAINTENANCE: A NEW TREATMENT PARADIGM?
Authors:
Jack Zuckerman
,
Robert Given
677 Lower risk of cardiovascular (CV) events and death in men receiving ADT by gonadotropin releasing hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists
Authors:
B. Tombal
,
P. Albertsen
,
A de la Taille
…
See all similar
Cited by
3
Cardiovascular Toxicity of Androgen Deprivation Therapy
Authors:
Julia Boland
,
William Choi
,
Maximillian Lee
…
Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer
Authors:
Celestia Higano
Relugolix – The novel oral androgen deprivation therapy for prostate cancer
Authors:
Rahul Jena
See all cited by